Pere Gascón
307 works · 13,339 citations · h-index 47
Top works
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
- The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
- A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
- Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
- Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases
- Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4
- Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity
- Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
- Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy
- Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives
- Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron
- Development of a new G-CSF product based on biosimilarity assessment
- Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)
- Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study
- Clinical experience with Zarzio® in Europe: what have we learned?
- Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity
- Anemia Management in Oncology and Hematology
- Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY
- Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells